Previous Article | Next Article 
Journal of Virology, November 1998, p. 9109-9115, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Neurovirulence in Feline Immunodeficiency Virus-Infected Neonatal
Cats Is Viral Strain Specific and Dependent on Systemic
Immune Suppression
C.
Power,1,*
R.
Buist,2
J. B.
Johnston,1
M. R.
Del
Bigio,3
W.
Ni,1
M. R.
Dawood,4 and
J.
Peeling3
Department of Clinical
Neurosciences,1 University of Calgary, Calgary,
Alberta T2N 4N1, and
Departments of
Radiology,2
Pathology,3 and
Medical
Microbiology,4 University of Manitoba,
Winnipeg, Manitoba R3E 0W3, Canada
Received 13 May 1998/Accepted 6 August 1998
 |
ABSTRACT |
Feline immunodeficiency virus (FIV) is a lentivirus that causes
immune suppression and neurological disease in cats. Among animal
viruses, individual viral strains have been shown to be neurovirulent,
but the role of viral strain specificity among lentiviruses and its
relationship to systemic immune suppression in the
development of neurological disease remains uncertain. To
determine the extent to which different FIV strains caused neurological disease, FIV V1CSF and Petaluma were compared in ex vivo
assays and in vivo. Both viruses infected and replicated in macrophage
and mixed glial cell cultures at similar levels, but V1CSF
induced significantly greater neuronal death than Petaluma in a
neurotoxicity assay. V1CSF-infected animals showed significant neurodevelopmental delay compared to the Petaluma-infected and uninfected animals. Magnetic resonance spectroscopy
studies of frontal cortex revealed significantly reduced
N-acetyl aspartate/creatine ratios in the V1CSF
group compared to the other groups. Cyclosporin A treatment of
Petaluma-infected animals caused neurodevelopmental delay and reduced
N-acetyl aspartate/creatine ratios in the brain. Reduced
CD4+ and CD8+ cell counts were observed in the
V1CSF-infected group compared to the uninfected and
Petaluma-infected groups. These findings suggest that
neurodevelopmental delay and neuronal injury is FIV strain
specific but that systemic immune suppression is also an important determinant of FIV-induced neurovirulence.
 |
INTRODUCTION |
Feline immunodeficiency virus
(FIV) is a lentivirus associated with immunological and
neurological abnormalities in cats (34), abnormalities
similar to those seen in human immunodeficiency virus type 1 (HIV-1)-infected individuals (28) and with other lentivirus
infections (32). Neurological disease may develop at the
onset of FIV infection, but it usually occurs as a complication of
acquired immunodeficiency syndrome (AIDS) (38), which is characterized by a decline in CD4+/CD8+
lymphocyte ratios and a weight loss in adult animals (3). The most common FIV-induced neurological syndrome, FIV encephalopathy, usually occurs after AIDS develops; affected animals present with ataxia, reduced motor activity, irritability, and disorientation (38). Experimental FIV studies reveal that behavioral
abnormalities occur in 20 to 40% of infected animals and are
accompanied by electrophysiological abnormalities, including delayed
visual and brainstem-evoked potentials, abnormal electroencephalograms,
and neuroradiological abnormalities such as cerebral atrophy and white matter lesions (35, 43). Studies indicate that FIV is a
neurotropic virus that infects microglia and astrocytes but not neurons
in vivo (7), a finding similar to the tropism displayed by
HIV-1 and simian immunodeficiency virus (SIV) in the brain.
Neuropathological changes accompanying FIV encephalopathy include
gliosis, white matter pallor, mineralization of the basal ganglia, and
microglial nodules (1, 16). Although multinucleated giant
cells have also been reported in FIV-infected cats (16), the
extent of inflammation in the brain is less than with other
lentiviruses, such as HIV-1, SIV, visna-maedi virus, or caprine
arthritis encephalitis virus (32). As reported for HIV-1 and
SIV infections, neuronal injury and death have been observed in
FIV-infected animals (29, 41). These neurological and
neuropathological observations suggest that FIV may share a common
pathogenesis with other lentiviruses.
The biochemical mechanisms underlying lentivirus encephalopathies are
uncertain but are presumed to be the consequence of direct viral
infection and/or activation of glial cells, resulting in increased
release of host and/or viral neurotoxic molecules (22).
Neuronal injury is common to most lentivirus infections, presumably due
to an excitotoxic mechanism in the brain involving increased neuronal
calcium influx and/or reduced intracellular uptake of glutamate
(20). These observations are supported by findings of
increased glutamate levels in the brains of FIV-infected cats showing
neuronal loss (41).
Individual viral strains and/or specific domains within viral genes of
animal retroviruses have been shown to be responsible for
neurovirulence or the development of neurological disease (15, 26, 46). Several studies indicate that some lentivirus strains may influence the extent of neurological disease (26, 36,
47), although the relationship between strain-dependent neurovirulence and systemic immune suppression remains uncertain. In
the present study, we examined the extent of neurovirulence caused by
different FIV strains and its relationship to systemic immune
suppression. A viral strain derived from cerebrospinal fluid caused
greater neuronal death as determined in an assay of neurotoxicity.
Infection of neonatal animals resulted in the rapid onset of
neurological disease and immune suppression in the group receiving the
viral strain derived from cerebrospinal fluid.
 |
MATERIALS AND METHODS |
Viruses and cell cultures.
The feline immunodeficiency
viruses used in this study included two primary isolates, V1CSF and
Petaluma (a gift from N. C. Pedersen), that underwent no more than
five in vitro passages before the present experiments. FIV V1CSF was
isolated from a cat with encephalopathy in Baltimore, Md., as
previously reported (41). Each virus was grown and titers of
the virus were determined on feline peripheral blood mononuclear cells
(PBMC) in RPMI 1640 with 15% fetal calf serum (FCS) and 1% penicillin
and streptomycin, initially stimulated with concavalin A (5 µg/ml)
for 3 days and subsequently treated with interleukin-2 (100 U/ml).
Tissue culture infectious doses (TCIDs) of each virus were determined
by limiting dilution in PBMC, as detected by reverse transcriptase (RT)
assay. Feline macrophages were prepared from PBMC by adherence on
polystyrene flasks for 3 days, following PBMC isolation in RPMI 1640 in
10% FCS and 1% penicillin and streptomycin, and then seeded at
105 cells per well in a 96-well plate. Mixed glial cell
(MGC) cultures were prepared from healthy adult cat cerebrum in
Dulbecco modified Eagle medium in 10% horse serum with antibiotics, as
described above and as previously reported (40), and seeded
at 105 cells per well in a 96-well plate. At 7 days
postadherence, macrophage and MGC cultures were infected in triplicate
wells with each virus at a titer of 103 50% TCID
(TCID50)/0.1 ml or heat-inactivated virus (boiled for 10 min). After infection of cultures, supernatants were harvested every 3 days for RT assay.
Neurotoxicity assay.
Neuronal cultures were prepared
from 12- to 15-week human gestational fetuses with the approval of the
Human Ethics Committee at the University of Manitoba as previously
reported (kindly provided by A. Nath [33, 40a]). This
culture system was selected because FIV infection of human astrocytes
and microglia is minimal (19). Hence, the neurotoxicity
induced by FIV-infected supernatants could be assessed directly,
avoiding infection of glial cells which may influence the extent of
neurotoxicity. Briefly, the tissue was mechanically dissociated, and
the cells were resuspended in Opti-MEM (Gibco) with 1%
heat-inactivated FCS, 1% N2 supplement (Gibco), and 1%
antibiotic solution (104 U of penicillin G per ml and 10 mg
of streptomycin B per ml in 0.9% NaCl) and then seeded in 96-well
microtiter plates at 105 cells per well and maintained for
a minimum of 4 weeks prior to experimental use. Sample wells were
immunostained for the neuronal marker, microtubule-associated protein 2 (MAP-2), and only cultures in which >70% of the cells were MAP-2
immunopositive were used for experiments. The remaining cells were
principally astrocytes, as indicated by glial acidic fibrillary protein
immunopositivity with rare microglia (>1%), which immunostained with
EBM-11 (39). Macrophage culture supernatants were harvested
at 4, 8, and 12 days postinfection, saved at
80°C, mixed (50 µl)
with Opti-MEM (0.1% FBS) (50 µl), and applied to the cultured
neurons for 3, 6, or 12 h. The neuronal cultures were stained
subsequently with trypan blue and fixed in 4% paraformaldehyde, and
the number of neurons with trypan blue-positive nuclei were counted per
unit area over five randomly chosen fields by an examiner who was
unaware of the specific treatment (40a). Neuronal death was
expressed as the percentage of trypan blue-stained neurons to the total number of neurons counted. Background neuronal death varied from 4 to
8% among cultures, depending on the age of the fetus and the duration
in culture; thus, background neuronal death was subtracted from the
level of toxicity for each experiment. Individual experiments were
conducted in triplicate wells and repeated at least twice.
Animals and virus inoculation.
Six specific-pathogen-free
pregnant cats (queens) were obtained through the University of Manitoba
Animal Services. All queens were negative for feline retroviruses as
determined by PCR. At day 1 postdelivery, all kittens were inoculated
intracranially in the right frontal lobe with 0.2 ml of titered virus
(103 TCID50/0.1 ml); V1CSF, n = 8; Petaluma, n = 6) or heat-inactivated virus (control;
n = 8) by a 30-gauge needle and syringe. Preliminary studies suggested that V1CSF and Petaluma differed in the extent to
which neurological disease and immune suppression was induced. Hence,
animals infected with Petaluma (n = 3) were treated
with cyclosporin A (CyA), which is a potent inhibitor of T-cell
function and proliferation, from 8 to 12 weeks postinfection. CyA was
administered daily at doses of 2.5 to 7.5 mg/ml subcutaneously. Weekly
measurements of renal function and CyA serum levels were performed,
ensuring that CyA was maintained in the therapeutic range (ca. 500 ng/ml), as recommended (14). Only one viral strain was used
for each litter to avoid cross-contamination and at least two litters
were infected per viral strain. Kittens were weaned at 6 weeks and monitored until 12 weeks of age, at which time they were euthanatized. Blood samples were obtained at 8 and 12 weeks postinfection from the
kittens from which PBMC had been prepared as described above.
Behavioral studies.
To determine neurobehavioral and
developmental features associated with FIV infection, the animals were
examined weekly and weighed by animal care staff who were unaware of
the infection status. The age (weeks) was recorded at which each
developmental milestone was manifested; these included playful
interaction, walking, running, air righting, the ability to walk along
a plank, and blink reflex, as adapted from Villablanca and Olmstead
(48). In addition, the height to which an animal jumped,
pursuing the moving light on a wall, was measured. At 12 weeks
following infection, five different parameters, including activity
level, play interaction, motor ability, inquisitiveness, and general
health, were scored by using the Feline Behavioral Scale (FBS). A
technician, unaware of the animal's infection status, ranked each
parameter depending on the level of impairment (5 [none] to 1 [extreme]) with a maximal score of 25.
In vivo magnetic resonance spectroscopy (MRS).
Animals were
anesthetised with 1.5 to 2.0% halothane administered through a nose
cone; the animals were then placed in an animal holder, and the coil
was taped into place on the head. Localized 1H MR spectra
of the left frontal cortex were obtained on week 12 postinfection by
using the STEAM localization method. A mixing time (TM) of 30 ms, an
echo time (TE) of 20 ms, and a repetition time (TR) of 2 s were
used. The voxel (VOI) size was 4 mm3 and was positioned by
using a scout image. Water suppression was accomplished by using a
CHESS sequence preceding the acquisition. Localized shimming and
radiofrequency amplitude adjustment was accomplished by using the
signal obtained from the VOI with the water suppression turned off. A
total of 512 signal averages were acquired, requiring a total
acquisition time per spectrum of 17.1 min. An elliptical surface coil
(5 cm × 2 cm) was used for the acquisition of both scout images
and spectra. The spectrometer used was a 7-T 21-cm Bruker/Biospec2
equipped with an actively shielded gradient coil set of ID 11.6 cm.
Spectra were processed by anodizing with a 15-Hz exponential
multiplication, Fourier transformation, and phasing, after which a
modest polynomial baseline correction was necessary. Peak intensities
were then measured and used to calculate metabolite ratios relative to
creatine, which is a stable metabolite in the brain (42).
Flow cytometry.
Blood was drawn at 8 and 12 weeks
postinfection. PBMC were divided into three equal aliquots. Each
aliquot (0.5 × 106 to 0.7 × 106
cells) was incubated for 1 h on ice with either murine antifeline CD4+ or CD8+ monoclonal antibodies (clones
FE1.7B12 and FE1.10E9, respectively; LABL, Davis, Calif.) or RPMI 1640 tissue culture media supplemented with 10% FCS. The cells were then
washed two times with serum-free RPMI 1640 medium to remove the unbound
antibodies. The cells were resuspended in 100 µl of RPMI 1640 medium
supplemented with 10% FCS, and 5 µl of goat anti-mouse
immunoglobulin G1 conjugated with fluorescein isothiocyanate (Cedarlane
Laboratory, Ltd., Hornby, Ontario, Canada) was added followed by
incubation on ice for 1 h. The cells were washed again as
described above and then resuspended in 200 µl of 0.5%
paraformaldehyde in phosphate-buffered saline. Flow cytometry analysis
was performed by using a Coulter Electronics EPICS 753 cell sorter with
the argon ion laser excitation set at 488 nm (500 mW).
Morphological studies.
At 12 weeks of age the animals were
deeply anesthetized and frontal craniotomies were performed to remove
the left frontal lobes. The abdomen of each animal was opened, and the
spleen was removed. Each animal was then perfused with 4%
paraformaldehyde, and the brain was fixed for 1 week, embedded in
paraffin, sectioned, and stained with hematoxylin, eosin, and luxol
fast blue. Histopathological analysis was performed on the frontal and
temporal lobes, thalamus, basal ganglia, brainstem, and cerebellum by a
qualified neuropathologist (M.R.D.B.). Each left frontal lobe was
frozen on dry ice and stored at
80°C for the PCR studies. Fixed
brain tissue from the frontal lobe, including the cortex, white matter,
and deep nuclei, was prepared for the immunocytochemistry analyses as
described previously (41) and immunostained with antibodies
to FIV p24 (clone 43-1B9, a gift from N. C. Pedersen).
Viral detection.
cDNA was synthesized from total RNA
extracted directly from the frontal lobe and the spleen of animals from
each group, as previously reported (50). The viral genome
was detected by amplification of a conserved region of the FIV
pol gene by nested PCR (41). Each reaction was
carried out in a mixture containing 0.2 mM each dNTP, 2.5 mM
MgCl2, 0.2 µM concentrations of each primer, 5 mM KCl, 1 mM Tris-HCl, and 0.25 U of Taq polymerase, to which 2 µl of template DNA was added for a total volume of 25 µl. A 770-bp fragment representing positions 3361 to 4131 of the pol gene
was amplified in an initial reaction of 30 cycles consisting of
95°C/min of denaturation, 40°C/min of annealing, and 72°C/2 min
of elongation by using primers 3361 (5'-AAGGATCCAGAAAAGATACTATGG-3') and 4131C (5'-GGCAACATTAGCTTTACCCCTGTTGG-3'). With 2 µl of the
primary PCR product as a template, a 192-bp fragment corresponding to
positions 3860 to 4052 of the pol gene was amplified by
using identical reagents in a second reaction of 35 cycles at an
annealing temperature of 50°C with primers 3860 (5'-CCAGATATGATGGAGGGAATCT-3') and 4052C (5'-CATATCCTGCATCTTCTGAACT-3'). A 26-mer oligonucleotide
probe (5'-TGTCAAACAATGATGATAATAGAAGG-3') was labeled with
[
-32P]dCTP and was used to probe the transferred gel
by routine Southern blot procedures that were designed to recognize
positions 3986 to 4012 contained in both reaction products.
Statistical tests.
The statistical tests comparing groups
were made by using nonparametric (Spearman correlation) or parametric
(analysis of variance [ANOVA]; Student's t test)
analyses.
 |
RESULTS |
Ex vivo viral tropism and neurotoxicity.
To determine the
tropism of the two FIV strains, adult feline macrophages and MGC
cultures were infected with V1CSF or Petaluma (Fig.
1A). Viral replication in macrophage and
MGC cultures, as indicated by mean fold increases in RT activity in
infected cultures relative to uninfected cultures, peaked at 8 days
postinfection for both V1CSF- and Petaluma-infected macrophage
cultures. Infected MGC showed significantly lower peak RT activities
than did the macrophage cultures infected by either virus
(P < 0.05). During the period of infection, the RT
values did not differ significantly between the two viruses at each
time point for both macrophage and MGC cultures.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 1.
Ex vivo macrophage and MGC tropism (A) and neurotoxicity
(B and C) of V1CSF and Petaluma. (A) The fold increase in supernatant
RT activity above uninfected cultures (± standard deviation) did not
differ between viruses at any time point, although the peak RT activity
was higher in the macrophage cultures than in the MGC cultures. Mean RT
levels in uninfected macrophage and MGC culture supernatants ranged
from 38 ± 10 to 56 ± 10 cpm/10 µl and did not differ
significantly between time points (ANOVA, P > 0.05).
(B) Neuronal death induced by supernatants from V1CSF-infected
macrophages was significantly higher than Petaluma or control
supernatants harvested at 4, 8, and 12 days postinfection. (C)
Comparison of neuronal killing after 3, 6, and 12 h of exposure to
CM revealed that V1CSF induced significantly greater neurotoxicity,
although the extent of the neurotoxicity did not differ between
exposure times (Student's t test; **, P < 0.001; *, P < 0.05).
|
|
To compare the relative neurotoxicities of conditioned media (CM)
from macrophages infected with V1CSF or Petaluma or in uninfected
cultures, we determined the percentage of neuronal death in human
fetal
neuronal cultures after treatment with CM that were harvested
at days
4, 8, and 12 postinfection (Fig.
1B). V1CSF-induced neurotoxicity
was
significantly greater than that caused by Petaluma or uninfected
controls at all three time points, with a maximum neurotoxicity
observed with CM derived from 4-day-old cultures for V1CSF (18
± 2.9%) and Petaluma (9.7 ± 1.9%) compared to those from controls
(1.4 ± 0.8%). The effects of the duration of CM exposure to
neuronal
cultures was also investigated (Fig.
1C) and revealed
that V1CSF
induced more neurotoxicity than Petaluma at all of the time
points
but that the level of neurotoxicity did not differ
significantly
among the various times of CM exposure. These
studies indicated
that both viruses showed similar cell tropisms but
that the induction
of neurotoxicity differed between the two viruses.
Neurobehavioral studies.
To determine whether individual
FIV strains differed in their in vivo neurovirulence, we developed a
model of FIV infection in which neurodevelopmental skills were compared
in neonates infected with V1CSF or Petaluma or sham infected with
heat-inactivated virus (V1CSF) (Table 1).
The groups did not differ in the mean age at which they acquired
neurodevelopmental skills until 6 weeks, when the V1CSF group were
observed to be significantly delayed in their ability to perform the
plank walk task compared to controls and the Petaluma group. In
addition, the V1CSF and Petaluma-CyA groups displayed significant
delays in blink reflex acquisition compared to the control and Petaluma
groups. At 11 weeks, the V1CSF and Petaluma-CyA groups showed a
significantly diminished mean jump height when pursuing a moving light
compared to the control and Petaluma groups. At 12 weeks, the total FBS
score was significantly less in the V1CSF and Petaluma-CyA groups
compared to the control group. Urea and creatinine levels in the
Petaluma-CyA group remained within the normal values (5 to 10 mmol/liter and 75 to 180 µmol/liter, respectively
[14]) throughout the experiments, indicating that the
neurobehavioral abnormalities were not due to CyA toxicity.
Neurobehavioral and weight gain differences were not observed among
individual litters infected with the same virus (Students t
test, P > 0.05). These findings suggested that the neurodevelopmental delay induced by FIV infection might be strain specific.
MRS studies.
To determine whether the neurodevelopmental
delays observed above were associated with neuronal injury, we examined
N-acetyl aspartate (NAA) levels in the brain, since this has
been shown to be a reliable indicator of neuronal integrity
(42). Spectra were recorded from the left frontal cortex
(Fig. 2A) at 6 and 12 weeks
postinfection. Comparison of the spectra at 12 weeks revealed that the
NAA levels were reduced in the V1CSF group but that the Petaluma and
control groups did not differ (Fig. 2B). When NAA and choline (Cho)
levels were expressed as a ratio, relative to creatine (Cr), the mean
NAA/Cr and Cho/Cr ratios did not differ among groups at 6 weeks (Fig.
3A). Conversely, the mean NAA/Cr ratio
was significantly less in the V1CSF and Petaluma-CyA groups compared to
the control and Petaluma groups, but the mean Cho/Cr ratios did not
differ between groups at 12 weeks postinfection (Fig. 3B). Comparisons
of NAA/Cr and Cho/Cr ratios in the thalamus did not reveal significant
differences among the groups (data not shown). When all of the animals
were compared at 12 weeks, NAA/Cr ratios were found to be significantly
correlated with FBS scores (Spearman, r = 0.83;
confidence interval = 0.43 to 0.95; P < 0.005).
These observations implied that neurodevelopmental delay caused by
different strains of FIV may occur due to neuronal injury and/or death
but that systemic immune suppression also influences neurovirulence.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2.
In vivo MRS of left frontal cortex. (A) Spectra were
recorded from deep in the mid-frontal sulcus. (B) Comparison of
representative spectra from each group of animals shows peaks
corresponding to NAA, Cho, and Cr peaks. NAA peaks were lower in the
V1CSF group than in the Petaluma and control groups.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of NAA/Cr and Cho/Cr (± standard errors of
the mean) ratios in the frontal cortex at 6 (A) and 12 (B) weeks
postinfection. (A) The mean NAA/Cr and Cho/Cr ratios did not differ
significantly between the groups at 6 weeks. (B) In contrast, the mean
NAA/Cr ratios were significantly lower in the V1CSF (n = 4) and Petaluma-CyA (n = 3) groups than in the
control (n = 4) and Petaluma (n = 4)
groups (Student's t test, P < 0.01), but
the mean Cho/Cr ratios did not differ among the groups. Two control
animals were excluded from the analysis since they represented extreme
outliers (greater than 2 standard deviations, P < 0.025).
|
|
CD4+ and CD8+ lymphocyte counts.
Since
enhanced systemic immunosuppression appeared to influence neurological
disease, fluorescence-activated cell sorter analysis of PBMC from the
animals was performed at 8 weeks postinfection, revealing that the mean
percentage of CD4+ cells did not differ among the control,
V1CSF, and Petaluma groups (Fig. 4A). At
12 weeks, however, the mean percentage of CD4+ cells was
significantly lower in the V1CSF animals compared to the control and
both Petaluma groups (P < 0.001). Comparison of the
mean percentage of CD8+ cells at 8 weeks (Fig. 4B)
indicated that both the Petaluma and the V1CSF groups were
significantly higher than the control group (P < 0.002). At 12 weeks, the mean percentage of CD8+ cells was
significantly higher in the Petaluma group compared to the V1CSF and
control groups (P < 0.001). However, the percentage of
CD8+ cells in the Petaluma-CyA group was significantly
lower than the Petaluma group at 12 weeks, indicating that low
CD8+ cell counts were common to both groups of animals with
neurodevelopmental delay and reduced NAA/Cr ratios.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Mean CD4+ (A) and CD8+ (B) cell
percentages in PBMC from control, V1CSF, and Petaluma groups at 8 and
12 weeks postinfection. CD4+ percentages did not differ at
8 weeks among the groups but were significantly lower in the V1CSF
group at 12 weeks postinfection than in the control and Petaluma groups
(ANOVA, P < 0.001). CD8+ percentages were
significantly higher in the Petaluma group than in the V1CSF and
control groups at both 8 weeks (P < 0.001) and 12 weeks (P < 0.001). The Petaluma-CyA and Petaluma
CD8+ cell counts did not differ at 8 weeks, but they
differed significantly at 12 weeks postinfection (P < 0.001; Student's t test).
|
|
Systemic illnesses.
To examine other systemic features
of FIV infection, weekly determinations of body weights indicated that
weight gain occurred in all of the groups but that in the V1CSF group.
The mean weights were significantly lower at 6, 9, and 12 weeks
postinfection than those of the control and the Petaluma-infected
groups (Fig. 5). Two animals in the V1CSF
group died at 4 and 6 weeks postinfection of pneumonia and diarrhea,
respectively. Similarly, three animals infected with V1CSF at an input
titer of 104 TCID50 were euthanatized at 4, 5, and 6 weeks postinfection after being judged by the University
Veterinary Services to be too ill, as evidenced by weight loss, gait
ataxia, and/or inability to feed, to continue in the studies. These
findings also suggested that marked systemic disease accompanied
neurodevelopmental delay and reduced NAA/Cr ratios.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 5.
Mean body weights of FIV-infected and control animals
over 12 weeks. The control and both Petaluma groups did not differ over
the entire experimental period, but at 6, 9, and 12 weeks postinfection
the V1CSF group showed significantly lower mean weights than did the
other groups (Student's t test; *, P < 0.05; **, P < 0.001).
|
|
Viral detection.
To determine whether viral RNA was
present in the tissues of infected animals, nested RT-PCR revealed
that the FIV genome was detectable in the brains of all of the animals
infected with V1CSF or Petaluma at 12 weeks postinfection but not in
the control animals (Fig. 6). Analysis of
RT-PCR products after one round of PCR at 30 cycles revealed detectable
FIV genome in two of six animals in the V1CSF group, three of six
animals in the Petaluma group, all animals in the Petaluma-CyA group,
and in none of the controls. In matched spleen samples, the viral
genome was detectable by nested PCR in all infected animals and in none
of the controls. Immunodetection of FIV p24 in sections from the
frontal lobe revealed no p24-positive cells in the four controls. In
contrast, p24 was detected in parenchymal and perivascular glia in
frontal-lobe sections from both the V1CSF (3 of 4) and Petaluma (3 of
4) groups at a frequency of 1 to 2 immunopositive cells (usually
perivascular) per section (1.5 cm2). These results suggest
that the viral burden in the brain was low and did not differ between
groups.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Southern blot detection of nested PCR amplification of
FIV pol cDNA in the left frontal lobe from sham-inoculated
control (n = 6), V1CSF-infected (n = 6), and Petaluma-infected (n = 6) animals at 12 weeks
postinfection. Representative animals from each group are shown except
for the Petaluma-CyA group. The FIV genome was detectable in the brains
of all Petaluma-, Petaluma-CyA-, and V1CSF-infected animals but not in
the controls.
|
|
Neuropathology.
The control sections revealed no
abnormalities. Sections from the V1CSF, Petaluma-CyA, and
Petaluma groups showed small collections of lymphocytes and
monocytes in the meninges, choroid plexus, and brain parenchyma of
infected animals in each group, but no marked differences between
groups were observed. Multinucleated cells and opportunistic processes
were not observed in any group.
 |
DISCUSSION |
In the present study, we have shown that neurodevelopmental
delay and reduced NAA/Cr ratios occurred in
V1CSF-infected but not in Petaluma-infected animals,
suggesting that neurovirulence in the present model is viral strain
specific. These in vivo observations are supported by ex vivo
studies in which V1CSF induced greater neurotoxicity than did Petaluma
despite a similar tropism in macrophages and MGC. However, systemic
abnormalities, including a decline in CD4+ and
CD8+ cells in the blood and a reduced weight gain, were
associated with the development of neurovirulence among the
V1CSF-infected animals. Increased systemic immunosuppression with CyA
treatment of Petaluma-infected animals also enhanced
neurodevelopmental delay and reduced NAA/Cr ratios in
brain. Taken together, these findings indicate that
individual FIV strains differ in their capacities to induce neuronal
injury in vivo and ex vivo but that systemic immune suppression is a
requisite feature of in vivo FIV-mediated neurovirulence in
neonates.
Several host and viral proteins released by cells of macrophage lineage
have been proposed as neurotoxins in lentiviral infections (20). An indirect mechanism of neuronal injury
and/or death is plausible because of the lack of evidence to
suggest that FIV infects neurons directly and the present
findings, in which molecules released from FIV-infected
macrophages were neurotoxic, results similar to those of studies
of other lentiviruses (11, 31). We used CM from 4, 8, and 12 days postinfection because preliminary studies from our
laboratory and earlier studies (10) suggested that viral
protein levels in CM varied over time. However, the peak neurotoxicity
was observed with CM from day 4, suggesting that viral production from
macrophages is not correlated with the extent of neurotoxicity. To some
extent, these ex vivo observations were also reflected in the current
in vivo findings of low viral burden in the brains of animals infected
with either virus. Nevertheless, it is possible that neuronal death
occurred due to the release of viral regulatory proteins expressed
early in infection (33), but these proteins were not
measured in the present studies. Neuronal death rates were lower in the
present studies than the levels reported for other similar
neurotoxicity assays (11), which may be due to the use of
fetal neurons, a heterogeneous neuronal population of which only a
subpopulation may be vulnerable to neurotoxins (27). While
it is conceivable that FIV-infected astrocytes in the human fetal brain
cultures released neurotoxic compounds, other studies from our group
indicate that FIV infection of human fetal astrocytes is minimal
(19). The findings of viral strain-specific induction of
neurotoxicity may account for the in vivo differences in neurovirulence
observed in the present study.
Studies of perinatal HIV-1 infection show neurodevelopmental delay in
as many as 50% of infected children (2) and that it may be
accompanied by diminished NAA/Cr ratios in pediatric brains
(6). However, the occurrence of HIV-1 and SIV infection in
children and young animals is usually accompanied by the entry of
inflammatory cells into the brain (44, 45). Studies with adult SIV-infected animals or HIV-infected adults indicate that inflammatory changes in the brain are not necessarily correlated with
neurocognitive dysfunction (12, 30). In the present study, there was limited inflammation observed in the brains of animals with
neurobehavioral and MRS evidence of neuronal dysfunction, suggesting
that in the FIV model inflammation is a limited predictor of
neurobehavioral abnormalities. In addition, unlike our earlier report
of V1CSF-infected adult animals (41), neuronal loss was not
apparent on the histological sections, despite the abnormalities observed by MRS. Detailed neuronal morphological studies and cell counts of the present animals may reveal differences between groups, as
reported for SIV and HIV encephalopathies in adults (8, 23).
However, neuronal loss has not been a principal feature of HIV-infected
children with neurodevelopmental delay, perhaps reflecting an increased
capacity of neurons in the developing brain to resist structural injury
even though they may manifest chemical abnormalities. This supposition
is confirmed by the significant improvement in total intelligence
quotient scores among HIV-infected children following aggressive
treatment with zidovudine (37). The present findings
taken together with earlier clinical-pathological correlations of both
HIV and SIV infection suggest that careful analysis of neurocognitive
function is a sensitive parameter by which the relative neurovirulence
of individual viruses may be compared.
The development of primary HIV-induced neurological disease, such as
encephalopathy, usually occurs in the setting of marked immune
suppression (28). A limited correlation between brain virus
load and HIV encephalopathy has been observed (18, 21). In contrast, systemic and/or cerebrospinal fluid viral loads were stronger predictors of the severity of encephalopathy, implying that
systemic factors such as immune suppression are also important determinants of neurological disease (5). Reduced
CD4+ cell counts have been reported for adolescents and
adults infected with different lentiviruses, including FIV
(3), SIV (25), and HIV-1 (13),
although the relationship between systemic immune suppression and
neurological disease is not well defined. Among FIV-infected adult
animals, an inversion of CD4/CD8 ratios has been associated with the
development of neurological abnormalities (38a). The current
studies showed a decline in CD4+ cells with the occurrence
of neurovirulence among the V1CSF-infected animals. As in earlier
studies (9), we observed a rise in CD8+
cell counts among infected animals at 8 weeks postinfection
compared to controls. However, CD8+ levels were
significantly lower in the V1CSF and Petaluma-CyA groups,
both of which showed neurological abnormalities, compared to the
Petaluma group at 12 weeks. CD8+ T cells, acting as
cytotoxic lymphocytes, may determine the extent to which FIV is cleared
from the blood or brain and to which the disease progresses
(17). Future studies focusing on the mechanism(s) by which
systemic immune suppression, especially the CD8+ cell
decline (49), influences the development of
neurovirulence are likely to reveal clues to lentivirus
neuropathogenesis.
Among several retroviral models of neurovirulence, individual viral
strains and specific domains within viral genes are responsible for the
development of neurological disease (15, 26, 46). The
present study confirms that the viral strain is also an important determinant of lentivirus-induced neurological disease, although the viral gene(s) responsible for inducing neurovirulence remains uncertain. It is notable that Petaluma and V1CSF were derived from
different tissue compartments and that sequence analysis of the surface
unit envelope region revealed multiple differing residues between
the two viruses used in the present studies (19). Although
Petaluma and V1CSF did not differ in their tropism for macrophages, MGC, or PBMC, the variation in env may have
other effects, such as influencing posttranslational processing and the
transport of envelope proteins, which has been correlated with
neurovirulence in murine retroviruses (24). Studies mapping the env domains responsible for neurodevelopmental delay are
currently in progress and may provide insight into the mechanisms of
FIV-induced neurovirulence.
 |
ACKNOWLEDGMENTS |
We thank T. Moench, M. Mayne, A. Nath, J. N. Simonsen, and K. Coombs for helpful discussions and T. Langelier, G. Nolette, D. Borowski, and S. McDonald for technical
assistance.
These studies were supported by the Hospital for Sick Children Research
Foundation (Toronto, Ontario, Canada), the Children's Hospital Research Foundation (Winnipeg, Manitoba, Canada) and the
Manitoba Health Research Council. C.P. is an NHRDP/MRC scholar.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Clinical Neurosciences, University of Calgary, Heritage Medical
Building, 107-3330 Hospital Dr., Calgary, AB Canada T2N 4N1. Phone:
(403) 220-5011. Fax: (403) 283-8731. E-mail:
power{at}ucalgary.ca.
 |
REFERENCES |
| 1.
|
Abramo, F.,
S. Bo,
M. G. Canese, and A. Poli.
1995.
Regional distribution of lesions in the central nervous system of cats infected with feline immunodeficiency virus.
AIDS Res. Hum. Retrovirus
11:1247-1253[Medline].
|
| 2.
|
Belman, A. L.
1992.
AIDS and the child's central nervous system.
Ped. Clin. North. Am.
39:691-714[Medline].
|
| 3.
|
Bendinelli, M.,
M. Pistello,
S. Lombardi,
A. Poli,
C. Garzelli,
D. Matteucci,
L. Ceccherini-Nelli,
G. Malvaldi, and F. Tozzini.
1995.
Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.
Clin. Microbiol.
8:87-112[Abstract].
|
| 4.
|
Boche, D.,
M. Hurtrel,
F. Gray,
M.-A. Claessens-Maire,
J.-P. Ganiere,
L. Montagnier, and B. Hurtrel.
1996.
Virus load and neuropathology in the FIV model.
J. Neurovirol.
2:377-387[Medline].
|
| 5.
|
Brew, B. J.,
L. Pemberton,
P. Cunningham, and M. G. Law.
1997.
Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage.
J. Infect. Dis.
175:963-966[Medline].
|
| 6.
|
Courtey, A.,
J. G. Jarvik,
R. E. Lenkinski,
R. I. Grossman,
I. Frank, and M. Delivoria-Papadopoulos.
1994.
Proton NMR spectroscopy of brain anomalies in neonates born to HIV-positive mothers.
Am. J. Radiol.
15:1853-1859.
|
| 7.
|
Dow, S. W.,
M. L. Poss, and E. A. Hoover.
1990.
Feline immunodeficiency virus: a neurotropic lentivirus.
J. Acquired Immune Defic. Syndr.
3:658-668.
|
| 8.
|
Everall, I. P.,
P. J. Luthert, and P. L. Lantos.
1991.
Neuronal loss in the frontal cortex in HIV infection.
Lancet
337:1119-1121[Medline]. (See comments.)
|
| 9.
|
George, J. W.,
N. C. Pedersen, and J. Higgins.
1993.
The effect of age on the course of experimental feline immunodeficiency virus infection in cats.
AIDS Res. Hum. Retroviruses
9:897-905[Medline].
|
| 10.
|
Giulian, D.,
K. Vaga, and C. A. Noonan.
1990.
Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1.
Science
250:1593-1596[Abstract/Free Full Text].
|
| 11.
|
Giulian, D.,
E. Wendt,
K. Vaca, and C. A. Noonan.
1993.
The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes.
Proc. Natl. Acad. Sci. USA
90:2769-2773[Abstract/Free Full Text].
|
| 12.
|
Glass, J. D.,
H. Fedor,
S. L. Wesselingh, and J. C. McArthur.
1995.
Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia.
Ann. Neurol.
38:755-762[Medline].
|
| 13.
|
Green, W. C.
1991.
The molecular biology of human immunodeficiency virus type 1 infection.
N. Engl. J. Med.
324:308-317[Medline].
|
| 14.
|
Gregory, C., and I. M. Gourley.
1992.
Renal tranplantation in clinical veterinary medicine, p. 870-878.
In
Current veterinary therapy, vol. XI. W. B. Saunders Co., Toronto, Ontario, Canada.
|
| 15.
|
Hasenkrug, K. J.,
S. J. Robertson,
J. Porti,
F. McAtee,
J. Nishio, and B. Chesebro.
1996.
Two separate envelope regions influence induction of brain disease by a polytropic murine retrovirus (FMCF98).
J. Virol.
70:4825-4828[Abstract].
|
| 16.
|
Hurtrel, M.,
J. P. Ganiere,
J. F. Guelfi,
L. Chakrabarti,
M. A. Maire,
F. Gray,
L. Montagnier, and B. Hurtrel.
1992.
Comparison of early and late feline immunodeficiency virus encephalopathies.
AIDS
6:399-406[Medline].
|
| 17.
|
Jeng, C. R.,
R. V. English,
T. Childers,
M. B. Tompkins, and W. A. F. Tompkins.
1996.
Evidence for CD8 antiviral activity in cats infected with feline immunodeficiency virus.
J. Virol.
70:2474-2480[Abstract].
|
| 18.
|
Johnson, R. T.,
J. D. Glass,
J. C. McArthur, and B. W. Chesebro.
1996.
Quantitation of human immunodeficiency virus in brains of demented and nondemented patients with acquired immunodeficiency syndrome.
Ann. Neurol.
39:392-395[Medline].
|
| 19.
|
Johnston, J. B., and C. Power.
1998.
Feline immunodeficiency virus tropism in human cells: evidence for strain-dependent infection.
FASEB J.
12:A809.
|
| 20.
|
Kolson, D. L., and R. J. Pomerantz.
1996.
AIDS dementia and HIV-1-induced neurotoxicity: possible pathogenic associations and mechanisms.
J. Biomed. Sci.
3:389-414[Medline].
|
| 21.
|
Lazarini, F.,
D. Seilhan,
O. Rosenblum,
S. Suarez,
L. Conquy,
T. Uchihara,
V. Sazdovitch,
K. Mokhtari,
F. Boussin,
C. Katlama,
F. Bricaire,
C. Duyckaerts, and J. Hauw.
1997.
Human immunodeficiency virus type 1 DNA and RNA load in brains of demented and nondemented patients with acquired immunodeficiency syndrome.
J. Neurovirol.
3:299-303[Medline].
|
| 22.
|
Lipton, S. D., and H. E. Gendelman.
1995.
Dementia associated with the acquired immunodeficiency syndrome.
N. Engl. J. Med.
332:934-940[Free Full Text].
|
| 23.
|
Luthert, P. J.,
M. M. Montgomery,
A. F. Dean,
R. W. Cook,
A. Baskerville, and P. L. Lantos.
1995.
Hippocampal neuronal atrophy occurs in rhesus macaques following infection with simian immunodeficiency virus.
Neuropathol. Appl. Neurobiol.
21:529-534[Medline].
|
| 24.
|
Lynch, W. P.,
W. J. Brown,
G. J. Spangrude, and J. L. Portis.
1994.
Microglial infection by a neurovirulent murine retrovirus results in defective processing of envelope protein and intracellular budding of virus particles.
J. Virol.
68:3401-3409[Abstract/Free Full Text].
|
| 25.
|
Mankowski, J. L.,
M. T. Flahery,
J. P. Spelman,
D. A. Hauer,
P. J. Didier,
A. M. Amedee,
M. Murphey-Corb,
L. M. Kirstein,
A. Munoz,
J. E. Clements, and M. C. Zink.
1997.
Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence.
J. Virol.
71:6055-6060[Abstract].
|
| 26.
|
Mankowski, J. L.,
J. P. Spelman,
H. G. Ressetar,
J. D. Strandberg,
J. Laterra,
D. L. Carter,
J. E. Clements, and M. C. Zink.
1994.
Neurovirulent simian immunodeficiency virus replicates productively in endothelial cells of the central nervous system in vivo and in vitro.
J. Virol.
68:8202-8208[Abstract/Free Full Text].
|
| 27.
|
Masliah, E.,
C. L. Achim,
N. Ge,
R. DeTeresa,
R. D. Terry, and C. A. Wiley.
1992.
Spectrum of human immunodeficiency virus-associated neocortical damage.
Ann. Neurol.
32:321-329[Medline].
|
| 28.
|
McArthur, J. C.
1987.
Neurologic manifestations of AIDS.
Medicine
66:407-437[Medline].
|
| 29.
|
Meeker, R. B.,
B. A. Thiede,
C. Hall,
R. English, and M. Tompkins.
1997.
Cortical cell loss in asymptomatic cats experimentally infected with feline immunodeficiency virus.
AIDS Res. Hum. Retrovirus
13:1131-1140[Medline].
|
| 30.
|
Murray, E. A.,
D. M. Rausch,
J. Lendvay,
L. R. Sharer, and L. E. Eiden.
1992.
Cognitive and motor impairments associated with SIV infection in rhesus monkeys.
Science
255:1246-1249[Abstract/Free Full Text].
|
| 31.
|
Namboodiri, A. M.,
C. N. Venkateshan,
R. Narayanan,
K. Blinder,
J. R. Moffett,
D. C. Gajdusek,
M. Gravell, and C. J. Gibbs, Jr.
1996.
Increased quinolinate immunoreactivity in the peripheral blood monocytes/macrophages from SIV-infected monkeys.
J. Neuro virol.
2:433-438[Medline].
|
| 32.
|
Narayan, O., and J. E. Clements.
1989.
Biology and pathogenesis of lentiviruses.
J. Gen. Virol.
70:1617-1639[Abstract/Free Full Text].
|
| 33.
|
Nath, A.,
K. Psooy,
C. Martin,
B. Knudsen,
D. S. Magnuson,
N. Haughey, and J. D. Geiger.
1996.
Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic.
J. Virol.
70:1475-1480[Abstract].
|
| 34.
|
Pedersen, N. C.,
E. W. Ho,
M. L. Brown, and J. K. Yanamoto.
1987.
Isolation of T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.
Science
235:790-793[Abstract/Free Full Text].
|
| 35.
|
Phillips, T. R.,
O. Prospero-Garcia,
D. L. Puaoi,
D. L. Lerner,
H. S. Fox,
R. A. Olmsted,
F. E. Bloom,
S. J. Henriksen, and J. H. Elder.
1994.
Neurological abnormalities associated with feline immunodeficiency virus infection.
J. Gen. Virol.
75:979-987[Abstract/Free Full Text].
|
| 36.
|
Phillips, T. R.,
O. Prospero-Garcia,
D. W. Wheeler,
P. C. Wagaman,
D. L. Lerner,
H. S. Fox,
L. R. Whalen,
F. E. Bloom,
J. H. Elder, and S. J. Henriksen.
1996.
Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR.
J. Neurovirol.
2:388-396[Medline].
|
| 37.
|
Pizzo, P. A.,
J. Eddy,
F. M. Balis,
R. F. Murphy,
H. Moss,
P. Wolters,
P. Brouwers,
P. Jaronsinski,
M. Rubin,
S. Broder,
R. Yarchoan,
A. Brunetti,
M. maha,
S. Nusionoff-Leherman, and D. G. Poplack.
1988.
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection.
New Engl. J. Med.
319:889-896[Abstract].
|
| 38.
|
Podell, M.,
M. Oglesbee,
L. Mathes,
S. Krakowka,
R. Olmstead, and L. Lafrado.
1993.
AIDS-associated ecephalopathy with experimental feline immunodeficiency virus infection.
J. Acquired Immune Defic. Syndr.
6:758-771.
|
| 38a.
|
Podell, M.,
K. Hayes,
M. Oglesbee, and L. Mathes.
1997.
Progressive encephalopathy associated with CD4/CD8 inversion in adult FIV-infected cats.
J. Acquired Immune Defic. Syndr. Hum. Retrovirol.
15:332-340[Medline].
|
| 39.
|
Power, C.,
P. A. Kong,
T. O. Crawford,
S. Wesselingh,
J. D. Glass,
J. C. McArthur, and B. D. Trapp.
1993.
Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations in the blood-brain barrier.
Ann. Neurol.
34:339-350[Medline].
|
| 40.
|
Power, C.,
J. C. McArthur,
R. T. Johnson,
D. E. Griffin,
J. D. Glass,
R. Dewey, and B. Chesebro.
1995.
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence.
Curr. Top. Microbiol. Immunol.
202:89-104[Medline].
|
| 40a.
|
Power, C.,
J. C. McArthur,
A. Nath,
K. Wehrly,
M. Mayne,
J. Nishio,
T. Langelier,
R. T. Johnson, and B. Chesebro.
1998.
Neuronal death induced by human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients.
J. Virol.
72:9045-9053[Abstract/Free Full Text].
|
| 41.
|
Power, C.,
T. Moench,
J. Peeling,
P. A. Kong, and T. Langelier.
1997.
Feline immunodeficiency virus causes increased glutamate levels and neuronal loss in brain.
Neuroscience
77:1175-1185[Medline].
|
| 42.
|
Prichard, J. W., and R. G. Shulman.
1986.
NMR spectroscopy of brain metabolism in vivo.
Ann. Rev. Neurosci.
9:61-85[Medline].
|
| 43.
|
Prospero-Garcia, O.,
N. Herold,
T. R. Phillips,
J. H. Elder,
F. E. Bloom, and S. J. Henriksen.
1994.
Sleep patterns are disturbed in cats infected with feline immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
91:12947-12951[Abstract/Free Full Text].
|
| 44.
|
Sassevile, V., and A. A. Lackner.
1997.
Neuropathogenesis of simian immunodeficiency virus infection in macaque monkeys.
J. Neurovirol.
3:1-9[Medline].
|
| 45.
|
Sharer, L. R.
1992.
Pathology of HIV-1 infection of the central nervous system: a review.
J. Neuropathol. Exp. Neurol.
51:3-11[Medline].
|
| 46.
|
Szurek, P. F.,
E. Floyd,
P. H. Yuen, and P. K. Wong.
1990.
Site-directed mutagenesis of the codon for Ile-25 in gPr80env alters the neurovirulence of ts1, a mutant of Moloney murine leukemia virus TB.
J. Virol.
64:5241-5249[Abstract/Free Full Text].
|
| 47.
|
Torsteinsdottir, S.,
G. D. Agnarsdottir,
S. D. Matthiasdottir,
B. Rafnar,
V. Andresdottir,
O. S. Andresson,
K. Staskus,
G. D. Petursson,
P. A. Palsson, and G. D. Georgsson.
1997.
In vivo and in vitro infection with two different molecular clones of visna virus.
Virology
229:370-380[Medline].
|
| 48.
|
Villablanca, J. R., and C. E. Olmstead.
1979.
Neurological development of kittens.
Dev. Psychobiol.
12:101-127[Medline].
|
| 49.
|
Walker, C. M., and J. A. Levy.
1989.
A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.
Immunology
66:628-630[Medline].
|
| 50.
|
Wesselingh, S. L.,
C. Power,
J. D. Glass,
W. R. Tyor,
J. C. McArthur,
J. M. Farber,
J. W. Griffin, and D. E. Griffin.
1993.
Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia.
Ann. Neurol.
33:576-582[Medline].
|
Journal of Virology, November 1998, p. 9109-9115, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zhu, Y., Vergote, D., Pardo, C., Noorbakhsh, F., McArthur, J. C., Hollenberg, M. D., Overall, C. M., Power, C.
(2009). CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J.
23: 2928-2941
[Abstract]
[Full Text]
-
Maingat, F., Vivithanaporn, P., Zhu, Y., Taylor, A., Baker, G., Pearson, K., Power, C.
(2009). Neurobehavioral Performance in Feline Immunodeficiency Virus Infection: Integrated Analysis of Viral Burden, Neuroinflammation, and Neuronal Injury in Cortex. J. Neurosci.
29: 8429-8437
[Abstract]
[Full Text]
-
Zhu, Y., Antony, J. M., Martinez, J. A., Glerum, D. M., Brussee, V., Hoke, A., Zochodne, D., Power, C.
(2007). Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression. Brain
130: 2011-2023
[Abstract]
[Full Text]
-
Heit, B., Jones, G., Knight, D., Antony, J. M., Gill, M. J., Brown, C., Power, C., Kubes, P.
(2006). HIV and Other Lentiviral Infections Cause Defects in Neutrophil Chemotaxis, Recruitment, and Cell Structure: Immunorestorative Effects of Granulocyte-Macrophage Colony-Stimulating Factor. J. Immunol.
177: 6405-6414
[Abstract]
[Full Text]
-
Zhu, Y., Antony, J., Liu, S., Martinez, J. A., Giuliani, F., Zochodne, D., Power, C.
(2006). CD8+ lymphocyte-mediated injury of dorsal root ganglion neurons during lentivirus infection: CD154-dependent cell contact neurotoxicity.. J. Neurosci.
26: 3396-3403
[Abstract]
[Full Text]
-
Zhu, Y., Jones, G., Tsutsui, S., Opii, W., Liu, S., Silva, C., Butterfield, D. A., Power, C.
(2005). Lentivirus Infection Causes Neuroinflammation and Neuronal Injury in Dorsal Root Ganglia: Pathogenic Effects of STAT-1 and Inducible Nitric Oxide Synthase. J. Immunol.
175: 1118-1126
[Abstract]
[Full Text]
-
Kubes, P., Heit, B., van Marle, G., Johnston, J. B., Knight, D., Khan, A., Power, C.
(2003). In Vivo Impairment of Neutrophil Recruitment during Lentivirus Infection. J. Immunol.
171: 4801-4808
[Abstract]
[Full Text]
-
Zhang, K., Rana, F., Silva, C., Ethier, J., Wehrly, K., Chesebro, B., Power, C.
(2003). Human Immunodeficiency Virus Type 1 Envelope-Mediated Neuronal Death: Uncoupling of Viral Replication and Neurotoxicity. J. Virol.
77: 6899-6912
[Abstract]
[Full Text]
-
Patrick, M. K., Johnston, J. B., Power, C.
(2002). Lentiviral Neuropathogenesis: Comparative Neuroinvasion, Neurotropism, Neurovirulence, and Host Neurosusceptibility. J. Virol.
76: 7923-7931
[Full Text]
-
Johnston, J. B., Power, C.
(2002). Feline Immunodeficiency Virus Xenoinfection: the Role of Chemokine Receptors and Envelope Diversity. J. Virol.
76: 3626-3636
[Abstract]
[Full Text]
-
Johnston, J. B., Silva, C., Power, C.
(2002). Envelope Gene-Mediated Neurovirulence in Feline Immunodeficiency Virus Infection: Induction of Matrix Metalloproteinases and Neuronal Injury. J. Virol.
76: 2622-2633
[Abstract]
[Full Text]
-
Johnston, J. B., Jiang, Y., van Marle, G., Mayne, M. B., Ni, W., Holden, J., McArthur, J. C., Power, C.
(2000). Lentivirus Infection in the Brain Induces Matrix Metalloproteinase Expression: Role of Envelope Diversity. J. Virol.
74: 7211-7220
[Abstract]
[Full Text]
-
Vahlenkamp, T. W., De Ronde, A., Schuurman, N. N. M. P., van Vliet, A. L. W., van Drunen, J., Horzinek, M. C., Egberink, H. F.
(1999). Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus. J. Gen. Virol.
80: 2639-2646
[Abstract]
[Full Text]